论文部分内容阅读
目的:观察加味瓜蒌散对门脉高压大鼠门静脉压力、肝纤维化指标的影响。方法:采用M ed lab-Ug4Cs生物信号采集处理系统、放免法,检测正常组、模型组、心得安对照组、加味瓜蒌散治疗组大鼠门静脉压力、肝纤维化指标。结果:模型组大鼠门静脉压力较正常组明显升高(P<0.01),加味瓜蒌散各剂量组、心得安对照组大鼠门脉压力较模型组明显下降(P<0.01),加味瓜蒌散各剂量组大鼠门脉压力与心得安治疗组比较,差异无显著性意义(P>0.05)。加味瓜蒌散各剂量组大鼠Ⅳ-C、PCⅢ、HA、LN与模型组比较均明显下降(P<0.01或P<0.05);而心得安组大鼠Ⅳ-C、PCⅢ、LN与模型组比较,差异无显著性意义(P>0.05),而HA明显升高(P<0.05)。结论:加味瓜蒌散能有效降低门静脉压力,在改善肝纤维化指标方面优于心得安。其作用机制可能与其良好的抗肝纤维化、阻止肝硬化形成、降低门脉压力、改善肝功能的作用有关。
OBJECTIVE: To observe the effect of Modified Gualou Powder on Portal Vein Pressure and Liver Fibrosis Index in portal hypertension rats. METHODS: M ed lab-Ug4Cs biological signal acquisition and processing system and radioimmunoassay were used to detect portal vein pressure and hepatic fibrosis indexes in normal group, model group, propranolol control group, and Jiawei Guayusan group. RESULTS: The portal vein pressure in the model group was significantly higher than that in the normal group (P<0.01). The portal pressure in each group of Jiawei Gualousan group and propranolol group was significantly lower than that in the model group (P<0.01). Compared with propranolol treatment group, the portal vein pressure of rats in each dose group had no significant difference (P>0.05). Compared with the model group, the IV-C, PCIII, HA, LN of the rats in the modified Gualou Powder group were significantly decreased (P<0.01 or P<0.05); and the IV-C, PCIII, LN and model in the propranolol group. There was no significant difference between the two groups (P>0.05), but HA was significantly higher (P<0.05). Conclusion: Modified Gualou Powder can effectively reduce the portal vein pressure and is superior to propranolol in improving liver fibrosis index. Its mechanism of action may be related to its good anti-fibrosis, prevention of cirrhosis, reduction of portal pressure, and improvement of liver function.